Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 19, 2018 (9 years ago)

Aripiprazole Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.

Affected NDC 60687-0179-01

Compare with the code on your package — it is the most precise check available.

Drug: Aripiprazole

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Aripiprazole
NDC 60687-0179
10 mg/1 Tablet
Oral
American Health Packaging Rx
Recalling firm
American Health Packaging
NDC code
60687-179-11
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0595-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Aripiprazole recalls

See all
Class II · Moderate risk

Aripiprazole Tablets USP

Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.

Ongoing Labeling / mix-up Ajanta Pharma USA Inc NDC 27241-056-03 D-0594-2026
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-011-13 D-0469-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-009-13 D-0468-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-008-13 D-0467-2024

Other recalls by American Health Packaging

All 2018 recalls
Class III · Low risk

Nitrofurantoin Capsules

Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.

Terminated Dissolution failure American Health Packaging NDC 68084-446-11 D-0880-2022